Our team brings together experts in hematology/medical oncology, immunology, stem cell transplantation, infectious diseases, pathology, radiation oncology, orthopedics and nursing to provide patients with exactly what they need to battle multiple myeloma and its physical, emotional and social side effects.
The Division is under the leadership of internationally-recognized experts David Siegel, M.D., Ph.D., chief, multiple myeloma and David Vesole, M.D., Ph.D., co-chief and director of research. JTCC plays a leading role in myeloma research and clinical trials and its research efforts have resulted in some of the most promising treatments for myeloma patients used today; Bortezomib (Velcade), Lenalidomide (Revlimid) and Carfilzomib (Kyprolis). In addition our team was a part of the development of the three newly approved myeloma therapies: Daratumumab (Darzalex), Elotuzumab (Empliciti), Ixazomib (Ninlaro).
We are a member of the Multiple Myeloma Research Consortium (MMRC) – a unique research model dedicated to accelerating development of novel, cutting-edge treatments for patients facing multiple myeloma. At the core of this unique model is the MMRC Tissue Bank, the only resource that integrates myeloma tissue samples with corresponding genomic and clinical data to enable researchers to rapidly advance research efforts.
Using new genome sequencing technologies, our JTCC researchers joined colleagues from 20 major North American research institutions to publish the first complete genomic portrait of multiple myeloma in the prestigious journal Nature. Building on these promising results, we enrolled patients in a follow-up study designed to uncover the molecular segments and variations of multiple myeloma. This study will be the centerpiece of the Multiple Myeloma Research Foundation’s (MMRF) Personalized Medicine Initiative, CoMMpass, aimed to accelerate translational research into therapeutic breakthroughs for patients.